346 related articles for article (PubMed ID: 26092709)
21. [Triple-negative breast carcinoma--rewiev of current literature].
Rubovszky G; Udvarhelyi N; Horváth Z; Láng I; Kásler M
Magy Onkol; 2010 Dec; 54(4):325-35. PubMed ID: 21163763
[TBL] [Abstract][Full Text] [Related]
22. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status in invasive breast cancer: a 3,198 cases study at National Cancer Center, China.
Zhu X; Ying J; Wang F; Wang J; Yang H
Breast Cancer Res Treat; 2014 Oct; 147(3):551-5. PubMed ID: 25234844
[TBL] [Abstract][Full Text] [Related]
23. Age-related frequency of triple negative breast cancer in women.
Sajid MT; Ahmed M; Azhar M; Mustafa QU; Shukr I; Ahmed M; Kamal Z
J Coll Physicians Surg Pak; 2014 Jun; 24(6):400-3. PubMed ID: 24953912
[TBL] [Abstract][Full Text] [Related]
24. Different prognostic factors correlate with Bcl-2 expression among triple negative and non-triple negative breast cancers.
Abd El-Hafez A; Shawky Mohamed Ael-A; Elesawy BH
Asian Pac J Cancer Prev; 2013; 14(2):1037-41. PubMed ID: 23621182
[TBL] [Abstract][Full Text] [Related]
25. Triple-negative breast cancer: advancements in characterization and treatment approach.
Hurvitz S; Mead M
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
[TBL] [Abstract][Full Text] [Related]
26. Metastatic triple-negative breast cancer.
Rakha EA; Chan S
Clin Oncol (R Coll Radiol); 2011 Nov; 23(9):587-600. PubMed ID: 21524569
[TBL] [Abstract][Full Text] [Related]
27. [Breast cancer with triple-negative phenotype in the Russian patient population. Clinical and morphologic features].
Zhukova LG
Vopr Onkol; 2015; 61(2):189-94. PubMed ID: 26087596
[TBL] [Abstract][Full Text] [Related]
28. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
29. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M
Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
[TBL] [Abstract][Full Text] [Related]
30. Directed therapy of subtypes of triple-negative breast cancer.
Carey LA
Oncologist; 2011; 16 Suppl 1():71-8. PubMed ID: 21278443
[TBL] [Abstract][Full Text] [Related]
31. Triple negative breast cancer: the kiss of death.
Jitariu AA; Cîmpean AM; Ribatti D; Raica M
Oncotarget; 2017 Jul; 8(28):46652-46662. PubMed ID: 28445140
[TBL] [Abstract][Full Text] [Related]
32. ABO blood type/Rh factor and the incidence and outcomes for patients with triple-negative breast cancer.
Yu J; Gao F; Klimberg VS; Margenthaler JA
Ann Surg Oncol; 2012 Oct; 19(10):3159-64. PubMed ID: 22878611
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of Lox in triple-negative breast cancer.
Leo C; Cotic C; Pomp V; Fink D; Varga Z
Ann Diagn Pathol; 2018 Jun; 34():98-102. PubMed ID: 29661738
[TBL] [Abstract][Full Text] [Related]
34. Promising therapeutic options in triple-negative breast cancer.
Bilici A; Arslan C; Altundag K
J BUON; 2012; 17(2):209-22. PubMed ID: 22740196
[TBL] [Abstract][Full Text] [Related]
35. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
36. Triple negative breast cancer in a poor resource setting in North-Western Tanzania: a preliminary study of 52 patients.
Rambau P; Masalu N; Jackson K; Chalya P; Serra P; Bravaccini S
BMC Res Notes; 2014 Jun; 7():399. PubMed ID: 24964871
[TBL] [Abstract][Full Text] [Related]
37. Biological subtypes of breast cancer: current concepts and implications for recurrence patterns.
Cadoo KA; Fornier MN; Morris PG
Q J Nucl Med Mol Imaging; 2013 Dec; 57(4):312-21. PubMed ID: 24322788
[TBL] [Abstract][Full Text] [Related]
38. Folate receptor α associated with triple-negative breast cancer and poor prognosis.
Zhang Z; Wang J; Tacha DE; Li P; Bremer RE; Chen H; Wei B; Xiao X; Da J; Skinner K; Hicks DG; Bu H; Tang P
Arch Pathol Lab Med; 2014 Jul; 138(7):890-5. PubMed ID: 24028341
[TBL] [Abstract][Full Text] [Related]
39. Triple negative breast cancer: therapeutic and prognostic implications.
Brady-West DC; McGrowder DA
Asian Pac J Cancer Prev; 2011; 12(8):2139-43. PubMed ID: 22292666
[TBL] [Abstract][Full Text] [Related]
40. [Comparison of biological behavior between triple-negative breast cancer and non-triple- negative breast cancer].
Ma JG; Wang NJ; Yu WJ
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Oct; 31(10):1729-32. PubMed ID: 22027778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
